Navigation Links
Essentialis Completes Patient Enrollment in Phase 2 Trial of DDCR for Treatment of Dyslipidemia
Date:11/23/2008

CARLSBAD, Calif., Nov. 23 /PRNewswire/ -- Essentialis Inc, a clinical stage pharmaceutical company, announced today that it has completed enrollment in a 92-patient Phase 2 trial of DCCR in dyslipidemic patients. The study encompasses both patients with very high triglycerides and mixed dyslipidemia and includes normal weight, overweight and obese patients presenting with or without hypertension.

The randomized, double-blind study is designed to assess the drug's effect on dyslipidemia and will evaluate three different doses of DCCR given over an 8-week period. Randomization was stratified by Body Mass Index (BMI) and concurrent use of statin drugs. The endpoints of the study include measurements of the effect of treatment on triglycerides, total-cholesterol, LDL-cholesterol, HDL-cholesterol and non-HDL-cholesterol, compared to placebo. The effects of DCCR on body weight, blood pressure and liver function tests compared to placebo are also being assessed. A total of 16 patients have completed the study, and an additional 20 have completed the double-blind treatment phase. The last patient last visit is scheduled for January 30th, 2009. Top-line results are anticipated in late March, 2009.

Commenting on this milestone achievement, Essentialis President and CEO, Iain Dukes said, "Essentialis is now closer to understanding the ability of DCCR to treat both very high triglycerides and mixed dyslipidemia, delivering a competitive profile of across the board lipid improvements with the added potential benefit of weight loss."

About DCCR

DCCR, diazoxide choline controlled release, is an ATP-dependent potassium channel agonist with potential utility in several cardiovascular and metabolic diseases. Extensive Phase 1 testing and investigator-sponsored clinical studies have demonstrated the drug's potential to lower triglycerides, non-HDL cholesterol and LDL-cholesterol while raising HDL-cholest
'/>"/>

SOURCE Essentialis Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
2. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
3. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
4. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
5. Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent
6. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
7. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
9. Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
10. Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
11. CuraGen Completes Enrollment in Phase II Trial of CR011-vcMMAE in Metastatic Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 2014   Ventana Medical Systems, Inc.  (Ventana), ... that its VENTANA System for Primary Diagnosis 1 ... Union for routine pathology, including primary diagnosis with ... Virtuoso software coupled with either the VENTANA iScan ... provides automated digital slide creation, case management and ...
(Date:8/20/2014)... BURLINGTON, Mass. , Aug. 20, 2014 ... Japanese electrophysiology (EP) mapping and ablation device ... increasingly use ablation to treat atrial fibrillation ... a primary treatment option for AF will ... for this application, such as advanced loop ...
(Date:8/20/2014)... 2014  Amerigen Pharmaceuticals Ltd. announces that its ... received Chinese FDA (CFDA) approval and has subsequently ... the China domestic market.  ... agreement with Sinochem Jiangsu Pharmaceutical Co., Ltd., Amerigen ... approved and China CFDA certified oral solid dose ...
Breaking Medicine Technology:Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 3Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 3Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic mark 2
... Sequenom, Inc. (Nasdaq: SQNM ) today announced ... company at the following conferences in November. ... ) Lazard Capital Markets 7th Annual ... York, NY Presentation date: Tuesday November 16, 2010 ...
... Pharmaceuticals today announced it has discovered that EVP-6124, its ... not previously seen in the scientific community: it acts ... By acting as a co-agonist and sensitizing ... amounts of naturally occurring ACh, typically found in individuals ...
Cached Medicine Technology:Sequenom to Present at Two Financial Conferences in November 2EnVivo Pharmaceuticals Research Shows EVP-6124 Acts as Acetylcholine Co-Agonist 2EnVivo Pharmaceuticals Research Shows EVP-6124 Acts as Acetylcholine Co-Agonist 3
(Date:8/20/2014)... The Institute for Integrative Nutrition ... to announce its new partnership with California ... university offering graduate programs featuring flexible learning. Graduates ... now eligible to receive six graduate credits towards ... , “I’m so thrilled to announce this new ...
(Date:8/20/2014)... "I decided that there needed to be ... manner without the hassles associated with using conventional oral ... patent-pending DR. GATES ORAL-HYGIENE TOOL provides an easy way ... good oral hygiene and fresh breath, and it eliminates ... affordable, eco-friendly and easy to use, the device is ...
(Date:8/20/2014)... acellular allogeneic nerve, from which Schwann cells, ... removed, reduced postoperative immune rejection. Simultaneously, chemically ... and base materials, such as the bottom ... a good scaffold in the process of ... similar to autologous nerve transplantation, can guide ...
(Date:8/20/2014)... 20, 2014 Doctors at the University of ... out mesothelioma in laboratory mice by injecting them with a ... details of the study on its website. Click here ... Hong Kong University’s AIDS Institute of Microbiology created a vaccine ... PD-1. By altering DNA, the vaccine is designed to prevent ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Attendees of ... a sneak peak at Los Angeles’ first multi-faceted food ... tour of a blossoming 1.5-acre high school campus urban ... shipping container farm in the L.A. Art District. , ... of sustainable urban agriculture, will kick off Seedstock’s “Reintegrating ...
Breaking Medicine News(10 mins):Health News:Integrative Nutrition Announces New Partnership with California Institute of Integral Studies 2Health News:Integrative Nutrition Announces New Partnership with California Institute of Integral Studies 3Health News:New Research Study Finds Vaccine Stops Mesothelioma in Lab Mice, According to Surviving Mesothelioma Website 2Health News:Seedstock Sustainable Agriculture Conference’s Urban Farm Field Trip to Offer First Look at Los Angeles’ Premier Food Business Incubator 2Health News:Seedstock Sustainable Agriculture Conference’s Urban Farm Field Trip to Offer First Look at Los Angeles’ Premier Food Business Incubator 3
... to minimize risk, experts say , TUESDAY, Jan. 19 (HealthDay ... such as heart disease, high blood pressure and diabetes, to ... challenge for an anesthesiologist to care for during surgery. , ... Dr. Kumar Belani, a professor of anesthesiology at the University ...
... causes problems similar to MS in humans, findings show ... in a gene called ZFP191 causes central nervous system ... occurs in humans with multiple sclerosis, new research has ... body attacks and destroys the myelin sheath that insulates ...
... The ... sclerosis) announced today that it has appointed Gordon S. LaVigne as chief development and ... ... , the nation’s leader in the fight against the disease ALS (amyotrophic laterals sclerosis) ...
... 11 A.M. , Justin Herman Plaza ... , www.walkforlifewc.c o m , Speakers and ... Jan. 19 A woman who walked away from her job as a ... a group intent on exposing abuses in the abortion industry will speak at the ...
... , PORT-AU-PRINCE, Haiti , ... Oxfam is working to overcome the challenges of delivering aid ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080221/DC14723LOGO ) , Although aid is beginning ... Haitian and international staff, the logistical challenges combined with a ...
... , JACKSONVILLE, Fla. and ... Medicine, Inc. ( www.USPreventiveMedicine.com ) will partner with the Iowa Chronic ... members not yet eligible for Medicare reduce health risks and live ... in equal amounts by a grant/cooperative agreement from the Centers for ...
Cached Medicine News:Health News:Excess Weight Poses Anesthesia Challenge 2Health News:Excess Weight Poses Anesthesia Challenge 3Health News:Gordon S. LaVigne Appointed ALS Association Chief Development and Communications Officer , 2Health News:Gordon S. LaVigne Appointed ALS Association Chief Development and Communications Officer , 3Health News:6th Annual Walk for Life West Coast Saturday, January 23, 2010 2Health News:Haiti Earthquake: One Week Later, Aid Agencies Facing Challenges 2Health News:Iowa Farm Bureau Introduces Bold Initiative to Improve Health Care for Rural Iowans 2Health News:Iowa Farm Bureau Introduces Bold Initiative to Improve Health Care for Rural Iowans 3Health News:Iowa Farm Bureau Introduces Bold Initiative to Improve Health Care for Rural Iowans 4
Stylish yet conservative, these classics are reliable, comfortable and durable....
Safilo Design, a state-of-the art ophthalmic collection that blends technology with minimalist sophistication. Each style comes with a sleek silver-colored hard case with magnetic closure....
Inquire...
Classic, stylish, and preppy, this collection features men's, women's and unisex styles....
Medicine Products: